Anticancer steroid sulfatase inhibitors: Synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography

Molecular Cancer Therapeutics

Volumn 7, Issue 8, 2008, Pages 2435-2444

  Woo, L W Lawrence ^a   Fischer, Delphine S ^a   Sharland, Christopher M ^a   Trusselle, Melanie ^a   Foster, Paul A ^b   Chander, Surinder K ^b   Di Fiore, Anna ^c   Supuran, Claudiu T ^d   De Simone, Giuseppina ^c   Purohit, Atul ^b   Reed, Michael J ^b   Potter, Barry V L ^a  

^a University of Bath   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c CNR   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY N 3,3,3 TRIFLUOROPROPYL 16,17 SECO ESTRA 1,3,5(10) TRIENE 16,17 IMIDE; 3 SULFAMOYLOXY N 3,3,3 TRIFLUOROPROPYL 16,17 SECO ESTRA 1,3,5(10) TRIENE 16,17 IMIDE; 667 COUMARIN; ANTINEOPLASTIC AGENT; ESTRONE; ESTRONE 3 O SULFAMIC ACID; STX 64; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BREAST CANCER; CONTROLLED STUDY; CRYSTALLIZATION; CRYSTALLOGRAPHY; DRUG SYNTHESIS; FEMALE; HYDROGEN BOND; HYDROPHOBICITY; IC 50; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; FEMALE; FLUORINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PROTEIN CONFORMATION; RATS; RATS, WISTAR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STERYL-SULFATASE;

EID: 53349089862     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0195     Document Type: Article

References (42)

1. Reed MJ, Purohit A, Woo LWL, Newman SP, Potter BVL. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev 2005;26:171-202.
2. Reed MJ, Purohit A, Woo LWL, Potter BVL. The Development of steroid sulfatase inhibitors. Rev Endocr Relat Cancer 1996;3:9-23.
3. Stanway SJ, Purohit A, Woo LWL, et al. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res 2006;12:1585-92.
4. Elger W, Schwarz S, Hedden A, Reddersen G, Schneider B. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Mol Biol 1995;55:395-403.
5. Purohit A, Woo LWL, Potter BVL, Reed MJ. In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. Cancer Res 2000;60:3394-6.
6. Foster PA, Newman SP, Chander SK, et al. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin Cancer Res 2006;12:5543-9.
7. Foster PA, Chander SK, Parsons MF, et al. Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Res Treat 2008;111:129-38.
8. Stanway SJ, Delavault P, Purohit A, et al. Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist 2007;12:370-4.
9. Fischer DS, Woo LWL, Mahon MF, Purohit A, Reed MJ, Potter BVL. D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase. Bioorg Med Chem 2003;11:1685-700.
10. Fischer DS, Chander SK, Woo LWL, et al. Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity. J Steroid Biochem Mol Biol 2003;84:343-9.
11. Purohit A, Williams GJ, Roberts CJ, Potter BVL, Reed MJ. In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Int J Cancer 1995;63:106-11.
12. Hernandez-Guzman FG, Higashiyama T, Pangborn W, Osawa Y, Ghosh D. Structure of human estrone sulfatase suggests functional roles of membrane association. J Biol Chem 2003;278:22989-97.
13. Woo LWL, Lightowler M, Purohit A, Reed MJ, Potter BVL. Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism. J Steroid Biochem Mol Biol 1996;57:79-88.
14. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727-48.
15. Eriksson AE, Jones TA, Liljas A. Refined structure of human carbonic anhydrase II at 2.0 A resolution. Proteins 1988;4:274-82.
16. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997;276:307-26.
17. Brunger AT, Adams PD, Clore GM, et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998;54:905-21.
18. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 1991;47:110-9.
19. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK - a program to check the stereochemical quality of protein structures . J Appl Crystallogr 1993;26:283-91.
20. Park BK, Kitteringham NR, O'Neill PM. Metabolism of fluorine-containing drugs. Annu Rev Pharmacol Toxicol 2001;41:443-70.
21. OSIRIS Property Explorer, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123 Allschwil, Switzerland. Available from: http://www.actelion.com/uninet/ www/www_main_p.nsf/Content/Technologies+Property+Explorer.
22. XLOGP, Molecular Design Laboratory, Institute of Physical Chemistry, Peking University, Beijing, China. Available from: ftp2.ipc.pku.edu.cn/pub/ software/xlogp/.
23. Reed JE, Woo LWL, Robinson JJ, et al. 2-Difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor. Biochem Biophys Res Commun 2004;317:16 9-75.
24. Woo LWL, Bubert C, Sutcliffe OB, et al. Dual aromatase-steroid sulfatase inhibitors. J Med Chem 2007;50:3540-60.
25. Howard JAK, Hoy VJ, O'Hagan D, Smith GT. How good is fluorine as a hydrogen bond acceptor? Tetrahedron 1996;52:12613-22.
26. O'Hagen D, Rzepa HS. Some influences of fluorine in bioorganic chemistry. Chem Commun1997;645-52.
27. Barbarich TJ, Rithner CD, Miller SM, Anderson OP, Strauss SH. Significant inter- and intramolecular O-H⋯·F-C hydrogen bonding. J Am Chem Soc 1999;121:4280-1.
28. Bohm HJ, Banner D, Bendels S, et al. Fluorine in medicinal chemistry. ChemBioChem 2004;5:637-43.
29. Shah P, Westwell AD. The role of fluorine in medicinal chemistry. J Enzyme Inhib Med Chem 2007;22:527-40.
30. Poirier D, Boivin RP. 17α-Alkyl- or 17α-substituted benzyl-17β-estradiols: a new family of estrone-sulfatase inhibitors. Bioorg Med Chem Lett 1998;8:1891-6.
31. Boivin RP, Luu-The V, Lachance R, Labrie F, Poirier D. Structure-activity relationships of 17α-derivatives of estradiol as inhibitors of steroid sulfatase. J Med Chem 2000;43:4465-78.
32. Woo LWL, Howarth NM, Purohit A, Hejaz HA, Reed MJ, Potter BVL. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J Med Chem 1998;41:1068-83.
33. Woo LWL, Purohit A, Malini B, Reed MJ, Potter BVL. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem Biol 2000;7:773-91.
34. Chander SK, Purohit A, Woo LWL, Potter BVL, Reed MJ. The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates. Biochem Biophys Res Commun 2004;322:217-22.
35. Ho YT, Purohit A, Vicker N, et al. Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. Biochem Biophys Res Commun 2003;305:909-14.
36. Vicker N, Ho Y, Robinson J, et al. Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. Bioorg Med Chem Lett 2003;13:863-5.
37. Leese MP, Leblond B, Smith A, et al. 2-Substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem 2006;49:7683-96.
38. Ireson CR, Chander SK, Purohit A, et al. Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats. Br J Cancer 2004;91:1399-404.
39. Abbate F, Winum JY, Potter BVL, et al. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg Med Chem Lett 2004;14:231-4.
40. Lloyd MD, Pederick RL, Natesh R, et al. Crystal structure of human carbonic anhydrase II at 1.95 A resolution in complex with 667-coumate, a novel anti-cancer agent. Biochem J 2005;385:715-20.
41. Lloyd MD, Thiyagarajan N, Ho YT, et al. First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors. Biochemistry 2005;44:6858-66.
42. Leese MP, Jourdan F, Gaukroger K, et al. Structure-activity relationships of C-17 cyanated estratrienes as anti-cancer agents. J Med Chem 2008;51:1295-308.